CAS: 73889-19-7; Tert-Butyl (1-Benzylpiperidin-4-yl)Carbamate

该化合物是一种化学化合物,其特性为管状核核心,即六人饱和氮环;一个苯基组位于一个位置,一个乙氧碳基(Boc)氨基组位于另一个位置,这有助于提高其结构复杂性和潜在的再活动性;三丁氧碳基组在有机合成中通常用作氨的防护组,允许有选择地作出反应,而不会干扰矿性功能;该化合物可能表现出管道性衍生物的典型特性,例如氮原子的基本特性,它可能参与各种化学反应,包括核分裂代代作用和组合反应;其应用可能涉及医药化学,特别是药物的开发,因为其结构模型能够影响生物活动;安全及处理考虑,以及许多有机化合物,包括适当储存和使用个人防护设备.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

Tert-Butyl N-(1-Benzoylpiperidin-4-yl)Carbamate 429677-00-9
N-(1-Benzylpiperidin-4-yl)Formamide 64951-43-5
4-氨基-1-苄基哌啶 4-Amino-1-Benzylpiperidin 50541-93-0
4-叔丁氧羰基氨基哌啶 Tert-Butyl Piperidin-4-Ylcarbamate 73874-95-0

合成工艺路线路线简述

    4-氨基-1-苄基哌啶 以90的收率获得产物1-苄基-4-(Boc-氨基)哌啶
    参考文献:Chem. Pharm. Bull. 2001,49(6),788-790
    标题:Chem. Pharm. Bull. 2001,49(6),788-790

    海关参考信息

    专利信息


    专利号:WO-2024132278-A1
    优先权日:2022-12-20
    标题:Synthesis, pharmacology and use of new water-soluble and selective fms-like tyrosine kinase 3 (flt3) inhibitors
    发明人:MAHBOOBI SAVOSH; WIRTH LUKAS; PONGARTZ HERWIG; SELLMER ANDREAS
    权利人:UNIV REGENSBURG
    摘要:The present application relates to compounds of formula (I) for inhibiting FLT3. The present application further relates to a composition, preferably pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof and comprising a pharmaceutically acceptable excipient and/or carrier. The present application also relates to a compound or composition for use in medicine. The present application also relates to a compound or composition for use in a method of preventing or treating cancer, preferably blood cancer, more preferably leukemia, even more preferably acute myeloid leukemia (AML). Furthermore, the present application relates to a method of preparing a compound.

    专利号:US-6469172-B2
    优先权日:2000-03-08
    标题:Process for the preparation of chemical compounds
    发明人:MALIGRES PETER E; LEE JAEMOON
    权利人:MERCK & CO INC
    摘要:An improved and efficient synthesis for the preparation of 2-amino-6-[(4-aminopiperidin-1-yl]methyl]pyridine, an intermediate compound in the preparation of muscarinic M3 receptor antagonists, includes as a final step the removal of trimethylacetyl and an amino protecting group from 2-trimethylacetyl-amino-6-[(4-protected aminopiperidin-1-yl)methyl]pyridine.

    专利号:EP-4389223-A1
    优先权日:2022-12-20
    标 题 :Synthesis, pharmacology and use of new water-soluble and selective fms-like tyrosine kinase 3 (flt3) inhibitors

    专利号:US-6649627-B1
    优先权日:1998-06-18
    标 题 :Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
    发明人:CECCHI ROBERTO; CROCI TIZIANO; GUZZI UMBERTO; MARSAULT ERIC
    权利人:SANOFI SYNTHELABO
    摘要:The invention concerns compounds of formula (Ia)whereinR1a represents hydrogen, an -S(O)z -(C1-C4)Alk group, a -CO(C1-C4)Alk group, an -NHSO2-(C1-C4)Alk group, an NCHl (C1-C4) Alk group, a 2-furyl group or a halogen;R2 represents hydrogen or a (C1-C4)Alk group, a (C1-C4) alkoxyl group, a halogen, -COOH, -COO(C1-C4)Alk, -CN, -CONR3R4, -NO2, -SO2NH2, -NHSO2(C1-C4)Alk;m and n are independently 0, 1 or 2;R3 and R4 independently represent hydrogen or a (C1-C4)Alk group;Z is 1 or 2and their salts or solvates, the pharmaceutical compositions that contain them, the process for their preparation, and intermediate synthesis products.
    常州市宣明医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://xuanmingchem.com
    电话:0519-85525329👤
    📞 常州市宣明医药科技有限公司⚠️参考联系方式

    电话: 0519-85525329
    邮件:sales@xuanmingchem.com
    网址: http://xuanmingchem.com
    地址:江苏省常州市新北区汉江路120号
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    江苏省常州市新北区汉江路120号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别. 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知